PKLR (Pyruvate Kinase, Liver and RBC) Drug Discovery Landscape & Assay Solutions
- By admin
- 31 Jul 2026
- Comments
Metabolic Precision Medicine: Enzymatic Activators, Genetic Deficiency Models, and High-Activity Assay Reagents for Hemolytic Anemia, Hemoglobinopathies, and Metabolic Disease.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PKLR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | PKLR Recombinant Protein, high purity (>95%), Sequence Verified, Theoretical MW ~58 kDa, endotoxin <1EU/µg, enzymatic activity ready. | View PKLR Products |
| Antigen (Mutant Panel) | PKLR Mutant Proteins (R510Q, R486W, G488S, delT506, R301Q) for pyruvate kinase deficiency screening. Mass Spec verified, sequence verified by NGS. | View PKLR Products |
| Gene Delivery | PKLR Premade Lentivirus (full-length ORF) for stable cell line construction in K562 or erythroid progenitor models. | View PKLR Products |
| Benchmark Ab | Anti-PKLR recombinant antibody, sequence verified, for Western/ELISA quantification. Positive control for assay normalization. | View PKLR Products |
| Validator | PKLR siRNA Set for knockdown verification in metabolic flux assays, validated for specificity without PKM2 off-target effects. | View PKLR Products |
| Related Target: PKM2 | Pyruvate Kinase M2 – oncogenic isoform critical for Warburg effect studies and cancer selectivity assays. Isoform counter-screening. | View PKM2 Products |
| Related Target: G6PD | Glucose-6-phosphate dehydrogenase – synergistic RBC metabolic pathway target for hemolytic anemia research. | View G6PD Products |
| Related Target: BCL11A | Erythroid lineage switch regulator; synergistic target for hemoglobinopathy combination strategies. | View BCL11A Products |
| Related Target: ALDOA | Aldolase A – upstream glycolytic enzyme for complete metabolic profiling. | View ALDOA Products |
| Related Target: HK1 | Hexokinase 1 – first committed step of glycolysis, essential for pathway-wide CRISPR screening controls. | View HK1 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allosteric Activation Site Screening | High-specific-activity WT PKLR (>95% purity, endotoxin <1EU/µg) with intact FBP binding domain for accurate kinetic profiling (Km, Vmax, Hill coefficient). |
| Genetic Variant Coverage (PK Deficiency) | Panel of 5 most prevalent mutant proteins (R510Q, R486W, G488S, delT506, R301Q) expressed in HEK293; sequence verified by NGS; E. coli and HEK293 expression systems available. |
| Isoform Selectivity (PKLR vs PKM2) | Parallel availability of PKLR and PKM2 recombinant proteins (>98% sequence homology discrimination) for counter-screening; mass spec verified; side-by-side enzymatic assays supported. |
| Species Translation (Mouse/Rat models) | Human/Mouse/Rat ortholog proteins available with conserved allosteric sites for preclinical pharmacology. |
| Cellular Metabolic Flux Validation | Validated siRNA sets for specific PKLR knockdown without PKM2 off-target effects; lentivirus particles for stable overexpression in primary erythroid progenitor cells. |
| Lack of Standardization / False Positives | Sequence Verified recombinant proteins, endotoxin controlled (<1EU/µg), research-grade benchmark antibody and validated siRNA included for assay controls and loading normalization. |
Live PKLR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (Pyruvate Kinase Deficiency)
- ➤ Latest Activator Research
- ➤ Resistance & Mutant Analysis
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The PKLR therapeutic landscape has shifted decisively from supportive care to precision enzymology. Following the approval of the first-generation small-molecule activator Mitapivat (AG-348) for pyruvate kinase deficiency (PKD), the field is aggressively expanding into sickle cell disease (SCD), thalassemia, and hereditary persistence of fetal hemoglobin (HPFH). Next-wave development focuses on tissue-specific activation profiles that distinguish erythrocyte PKLR from hepatic PKLR, minimizing hepatic metabolic disruption. Concurrently, oncology programs targeting the glycolytic switch (PKM2 inhibition vs PKLR activation) require sophisticated enzymatic selectivity panels. Emerging research also explores PKLR modulation in metabolic disorders such as MASH/NASH, where liver-specific allosteric inhibitors or siRNA approaches may offer new therapeutic avenues. Future differentiation hinges on mutant-agnostic activation profiles, stringent PKM2 isoform selectivity (>100-fold selectivity expected), and synergistic combination with gene-editing modalities (CRISPR, base editing).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Allosteric Activator | Agios (Mitapivat), Forma Therapeutics (Novo Nordisk) | PKD, SCD, Thalassemia | Enzymatic Activation Assay: high-purity WT & mutant PKLR proteins for mutant rescue profiling |
| Gene Therapy / Lentiviral Delivery | Rocket Pharma, Beam Therapeutics, Editas | Severe PKD | Transduction Validation: full-length ORF lentivirus for stable CD34+ cell overexpression; mutant PKLR proteins as rescue benchmarking standards |
| Base Editing (Corrective) | Beam Therapeutics | PKD (corrective editing) | Mutant vs WT Protein Standards: quantitative Western controls for editing efficiency |
| Allosteric Inhibitor (Oncology) | Emerging Biotechs | Solid Tumors (PKM2 targeting) | Isoform Selectivity Assay: parallel PKLR & PKM2 recombinant proteins for selectivity index determination |
| siRNA / ASO (Liver-Metabolic) | Emerging Biotechs | MASH/NASH | Knockdown Verification: high-spec siRNA sets for PKLR silencing in hepatocytes |
Key Mutations & Targeted Therapeutics
PKLR deficiency is caused by over 300 documented mutations. The TarMart mutant protein panel focuses on the most prevalent disease-associated variants validated in clinical databases:
- R510Q (PKHYP; dbSNP rs118204087): Common in PK deficiency, impacts enzyme stability.
- R486W (CNSHA2; dbSNP rs1484388413): Thermolabile mutation, reduces catalytic efficiency.
- G488S (CNSHA2): Kinetic defect, reduces substrate binding.
- delT506 & R301Q: Additional frequent mutations with implications for allosteric activator sensitivity.
These mutant proteins are available in >95% purity, sequence verified, and suitable for high-throughput screening to identify broad-spectrum activators or assess variant-specific drug responses.